Page 1

August 5 , 2021 Aurinia ™ Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights - $ 6.6 million in net revenue for the second quarter 2021 ( 624 % increase from first quarter 2021 ) - - 415 patient start forms ( PSFs ) received for LUPKYNIST during the second quarter ( over a 60 % increase from the first quarter 2021 ) and over 800 PSFs received year - to - date - - Continued ex - U.S . execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka – - Cash and cash equivalents , and investments of $ 323.7 million at June 30 , 2021 – - Conference call to be hosted today at 4:30 p.m. EDT — VICTORIA , British Columbia -- ( BUSINESS WIRE ) -- Aurinia Pharmaceuticals Inc. ( NASDAQ : AUPH ) ( " Aurinia " or the " Company " ) today issued its financial results for the second quarter ended June 30 , 2021. Amounts , unless specified otherwise , are expressed in U.S. dollars . " Aurinia continues to make progress toward transforming the treatment of lupus nephritis ( LN ) by improving access to treatment and providing disease education and care for the long underserved LN patient community , " said Peter Greenleaf , President and Chief Executive Officer of Aurinia . " Our second quarter results demonstrate our momentum as COVID related restrictions are loosened in parts of the United States with a significant increase in both revenue and patient start forms . We are confident that with this year - to - date performance and a strong balance sheet , that we are well - poised for growth as we continue our work to expand the treatment of LN and seek new opportunities that could address the needs of patients with serious autoimmune disorders . " Mr. Greenleaf further stated , “ As we continue to expand patient access to LUPKYNIS across the United States , we anticipate that annual net revenue for LUPKYNIS will be in the range of $ 40 to $ 50 million for 2021 , setting Aurinia up for a very strong 2022 as we recognize the benefit of patients continuing on therapy and hopefully achieving reductions in their proteinuria . " Recent Highlights Second Quarter 2021 U.S. Commercial Activities • 415 PSFS during the second quarter with over 800 PSFs received year - to - date ; • As of June 30 , 2021 , a total of 45 LUPKYNIS - specific policies had been published by insurers representing approximately 110 million covered lives in the U.S .; and • Converted over 50 % of PSFs to patients on therapy by the end of the second quarter .